Singapore, June 15, 2024 – ChemT Biotechnology was recently featured in the NUS Alumni Magazine for its pioneering work in applying artificial intelligence to biologics manufacturing. The article highlights how ChemT Bio’s proprietary AI platform is addressing key industry challenges—from improving production efficiency and process transparency to enhancing global access to advanced therapies.

Ms. Jie Sun, CEO & Co-founder and NUS alumna, shared the company’s values-driven mission: “It’s an honor to be recognized by our academic roots. At ChemT Bio, we are committed to applying the principles we learned at NUS to drive innovations that benefit public health. Our AI-powered solutions are designed to make high-quality biologics scalable, affordable, and accessible to patients worldwide.”

The feature emphasized ChemT Bio’s progress in three core areas:

• Process Transparency

• Access and Affordability

• AI Innovation

The full article in the NUS Alumni Magazine explores how ChemT Bio’s platform translates cutting-edge research into practical solutions with real-world impact.